PMS48 - COST PER RESPONDER ANALYSIS FOLLOWING A 24-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ETANERCEPT FROM THE PORTUGUESE PAYER PERSPECTIVE
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.1762
https://www.valueinhealthjournal.com/article/S1098-3015(18)35064-2/fulltext
Section Title :
Section Order :
1127
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35064-2&doi=10.1016/j.jval.2018.09.1762